Market Research Logo

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma – Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Metastatic Uveal Melanoma Overview
Therapeutics Development
Pipeline Products for Metastatic Uveal Melanoma - Overview
Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis
Metastatic Uveal Melanoma - Therapeutics under Development by Companies
Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes
Metastatic Uveal Melanoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Metastatic Uveal Melanoma - Products under Development by Companies
Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes
Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development
Bellicum Pharmaceuticals Inc
Celldex Therapeutics Inc
Eli Lilly and Company
Novartis AG
Spectrum Pharmaceuticals Inc
Metastatic Uveal Melanoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alpelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPX-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emibetuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glembatumumab vedotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LXS-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sotrastaurin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vincristine sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metastatic Uveal Melanoma - Dormant Projects
Metastatic Uveal Melanoma - Discontinued Products
Metastatic Uveal Melanoma - Product Development Milestones
Featured News & Press Releases
Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016
Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Uveal Melanoma, H2 2016
Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Metastatic Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
Metastatic Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016
Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016
Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2016
Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Metastatic Uveal Melanoma - Dormant Projects, H2 2016
Metastatic Uveal Melanoma - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Metastatic Uveal Melanoma, H2 2016
Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report